Gull Labs
This article was originally published in The Gray Sheet
Executive Summary
Cash acquisition of diagnostic test kit and reagent-maker Meridian Diagnostics is valued at $3 per share, or roughly $43 mil. For the 12 months ended Sept. 30, 1997, the company booked net income of nearly $6 mil. on sales of $35.2 mil. Gull, a Salt Lake City-based unit of Fresenius, markets diagnostic test kits for infectious diseases and autoimmune disorders